Skip to content

NIAGEN BIOSCIENCE, INC.

NASDAQ: NAGE

Company: Niagen Bioscience
Ticker: Nasdaq: NAGE
Sector: Consumer
Investor Contact: Ben Shamsian

Niagen Financials

Financials – Current & Historical

CONSOLIDATED BALANCE SHEETS
v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents, including restricted cash of $152 for both periods presented $ 44,660 $ 27,325
Inventories 9,192 14,525
Prepaid expenses and other assets 2,482 2,450
Total current assets 64,102 49,534
Leasehold improvements and equipment, net 1,719 2,137
Intangible assets, net 359 510
Right-of-use assets 1,730 2,400
Other long-term assets 368 383
Total assets 68,278 54,964
Current liabilities    
Accounts payable 8,526 10,232
Accrued expenses 7,817 9,493
Current maturities of operating lease obligations 982 691
Current maturities of finance lease obligations 12 11
Customer deposits 611 195
Total current liabilities 17,948 20,622
Deferred revenue 2,579 3,311
Operating lease obligations, less current maturities 1,657 2,563
Finance lease obligations, less current maturities 0 12
Total liabilities 22,184 26,508
Commitments and Contingencies (Notes 10 and 16)
Stockholders' Equity    
Common stock, $0.001 par value; authorized 150,000 shares; 77,330 shares and 74,981 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively. 77 75
Additional paid-in capital 227,931 218,845
Accumulated deficit (181,910) (190,460)
Cumulative translation adjustments (4) (4)
Total stockholders' equity 46,094 28,456
Total liabilities and stockholders' equity 68,278 54,964
Nonrelated Party    
Current assets    
Trade receivables, net of allowances of $95 and $68, respectively; including receivables from Related Party of zero and $2.8 million, respectively. $ 7,768 $ 5,234
CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)
v3.25.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Restricted cash $ 152 $ 152
Trade receivables, allowance $ 95 $ 68
Common stock par value (in dollars per share) $ 0.001 $ 0.001
Common stock authorized (in shares) 150,000 150,000
Common stock issued (in shares) 77,330 74,981
Common stock outstanding (in shares) 77,330 74,981
Related Party    
Trade receivables $ 0 $ 2,800
CONSOLIDATED STATEMENTS OF INCOME
v3.25.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Sales, net $ 99,597 $ 83,570
Cost of sales 38,011 32,790
Gross profit 61,586 50,780
Operating expenses:    
Sales and marketing 29,469 26,438
Research and development 6,016 4,958
General and administrative 18,375 24,983
Total operating expenses 53,860 56,379
Operating income (loss) 7,726 (5,599)
Nonoperating income:    
Interest income, net 1,129 661
Income before provision for income taxes 8,855 (4,938)
Provision for income taxes 305 0
Net income (loss) $ 8,550 $ (4,938)
Net income (loss) per share attributable to common stockholders    
Basic (in dollars per share) $ 0.11 $ (0.07)
Diluted (in dollars per share) $ 0.11 $ (0.07)
Weighted average common shares outstanding    
Basic (in shares) 75,929 74,985
Diluted (in shares) 78,125 74,985
CONSOLIDATED STATEMENTS OF CASH FLOWS
v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash Flows From Operating Activities    
Net income (loss) $ 8,550 $ (4,938)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation of leasehold improvements and equipment 663 870
Amortization of intangibles 151 158
Noncash lease expense 670 677
Share-based compensation expense 3,656 4,751
Gain on sale or disposal of leasehold improvements and equipment (19) (5)
Allowance for (Recovery of) credit losses (1,255) 964
Reversal of previously accrued royalties and license maintenance fees (3,521) 0
Loss from impairment of intangibles 0 3
Non-cash financing costs 80 75
Changes in operating assets and liabilities:    
Trade receivables (1,279) 2,255
Inventories 5,333 152
Implementation costs for cloud computing arrangement (83) (60)
Prepaid expenses and other assets (45) 631
Accounts payable (1,067) 553
Accrued expenses 1,206 2,156
Deferred revenue (732) (644)
Customer deposits and other 416 38
Operating lease liabilities (615) (519)
Net cash provided by operating activities 12,109 7,117
Cash Flows From Investing Activities    
Purchases of leasehold improvements and equipment (163) (148)
Proceeds from the sale of leasehold improvements and equipment, net 20 5
Net cash used in investing activities (143) (143)
Cash Flows From Financing Activities    
Proceeds from exercise of stock options 5,432 0
Payment of debt issuance costs (52) (75)
Principal payments on finance leases (11) (15)
Net cash provided by (used in) financing activities 5,369 (90)
Net increase in cash and cash equivalents 17,335 6,884
Cash and cash equivalents, including restricted cash of $152 for both periods - beginning of year 27,325 20,441
Cash and cash equivalents, including restricted cash of $152 for both periods - end of year 44,660 27,325
Supplemental Disclosures of Cash Flow Information    
Cash payments for interest on finance leases 1 2
Cash payments for principal on operating lease liabilities 600 610
Supplemental Schedule of Noncash Operating Activity    
Adjustment to retained earnings, cumulative effect of initially adopting ASC 326 (46,094) (28,456)
Right-of-use assets and operating lease obligations reduced for entering into lease amendment 0 446
Cumulative Effect, Period of Adoption, Adjustment    
Supplemental Schedule of Noncash Operating Activity    
Adjustment to retained earnings, cumulative effect of initially adopting ASC 326 $ 0 $ 29
CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL)
v3.25.0.1
Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Cash Flows [Abstract]      
Restricted cash $ 152 $ 152 $ 152
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Accumulated  Deficit
Accumulated  Deficit
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Translation  Adjustments
Beginning balance (in shares) at Dec. 31, 2022     74,567        
Beginning balance at Dec. 31, 2022 $ 28,672 $ (29) $ 74 $ 214,094 $ (185,493) $ (29) $ (3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of restricted stock (in shares)     414        
Issuance of restricted stock 1   $ 1        
Share-based compensation (in shares)     25        
Share-based compensation 4,751     4,751      
Translation adjustment (1)           (1)
Net income (loss) (4,938)       (4,938)    
Ending balance (in shares) at Dec. 31, 2023     74,981        
Ending balance at Dec. 31, 2023 28,456 (29) $ 75 218,845 (190,460)   (4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of restricted stock (in shares)     271        
Issuance of restricted stock 0            
Exercise of stock options (in shares)     2,053        
Exercise of stock options 5,432   $ 2 5,430      
Share-based compensation 3,656     3,656      
Net income (loss) 8,550       8,550    
Ending balance (in shares) at Dec. 31, 2024     77,330        
Ending balance at Dec. 31, 2024 $ 46,094 $ 0 $ 77 $ 227,931 $ (181,910)   $ (4)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (PARENTHETICAL)
v3.25.0.1
Consolidated Statements of Stockholders' Equity (Parenthetical)
12 Months Ended
Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]  
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-13 [Member]

Arrow